Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- None.
- None.
In connection with the commencement of their employment, the employees received options on August 1, 2023 to purchase an aggregate 606,860 shares of Insmed common stock at an exercise price of
The options have a 10-year term and a four-year vesting schedule, with
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301891818.html
SOURCE Insmed Incorporated
FAQ
What is the latest announcement from Insmed Incorporated (Nasdaq: INSM)?
How many shares were granted to the new employees?
What is the exercise price of the granted shares?